After M&A stretch, Pfizer CEO says company needs 'breathing period' from large deals

Amid a recent biopharma M&A resurgence, one major player plans to stay out of the waters after making multiple recent splashes.

Though not for lack of business development capacity, Pfizer is currently taking a large dealmaking “breathing period,” CEO Albert Bourla told investors this week at Goldman Sachs’ 2024 annual Global Healthcare Conference in Miami.